Given the impressive results in overall efficacy and tolerability, in 2018, oral osimertinib became, and currently remains, standard of care (SOC) for stage IV, EGFR-mutant (ex19del, L858R) NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.